![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FAM49A |
Gene summary for FAM49A |
![]() |
Gene information | Species | Human | Gene symbol | FAM49A | Gene ID | 81553 |
Gene name | CYFIP related Rac1 interactor A | |
Gene Alias | CYRI-A | |
Cytomap | 2p24.2 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q9H0Q0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
81553 | FAM49A | male-WTA | Human | Thyroid | PTC | 2.76e-28 | 7.42e-02 | 0.1037 |
81553 | FAM49A | PTC01 | Human | Thyroid | PTC | 1.37e-12 | 1.82e-02 | 0.1899 |
81553 | FAM49A | PTC04 | Human | Thyroid | PTC | 3.84e-09 | 1.76e-01 | 0.1927 |
81553 | FAM49A | PTC05 | Human | Thyroid | PTC | 6.29e-12 | 3.52e-01 | 0.2065 |
81553 | FAM49A | PTC06 | Human | Thyroid | PTC | 2.90e-16 | 3.71e-01 | 0.2057 |
81553 | FAM49A | PTC07 | Human | Thyroid | PTC | 3.83e-24 | 2.96e-01 | 0.2044 |
81553 | FAM49A | ATC12 | Human | Thyroid | ATC | 2.44e-03 | -2.63e-01 | 0.34 |
81553 | FAM49A | ATC13 | Human | Thyroid | ATC | 5.43e-04 | -2.77e-01 | 0.34 |
81553 | FAM49A | ATC4 | Human | Thyroid | ATC | 8.17e-04 | -2.53e-01 | 0.34 |
81553 | FAM49A | ATC5 | Human | Thyroid | ATC | 1.46e-03 | -2.74e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAM49A | SNV | Missense_Mutation | c.827N>G | p.Ser276Cys | p.S276C | Q9H0Q0 | protein_coding | deleterious(0) | benign(0.283) | TCGA-E9-A1NA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
FAM49A | insertion | Nonsense_Mutation | novel | c.449_450insAATGAATGATACATAGTTTTTTAAGGTATTTTTGCCAATCCAAT | p.Ile151MetfsTer5 | p.I151Mfs*5 | Q9H0Q0 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
FAM49A | insertion | Nonsense_Mutation | novel | c.352_353insTTACTTATTTTAAGGTTCTGAGTTCGTAGTATAGTTAGT | p.Thr118delinsIleThrTyrPheLysValLeuSerSerTerTyrSerTerSer | p.T118delinsITYFKVLSS*YS*S | Q9H0Q0 | protein_coding | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR | ||
FAM49A | SNV | Missense_Mutation | novel | c.182A>G | p.Glu61Gly | p.E61G | Q9H0Q0 | protein_coding | deleterious(0.01) | possibly_damaging(0.864) | TCGA-C5-A1BN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
FAM49A | SNV | Missense_Mutation | novel | c.626N>T | p.Ser209Phe | p.S209F | Q9H0Q0 | protein_coding | deleterious(0) | possibly_damaging(0.675) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
FAM49A | SNV | Missense_Mutation | rs775108109 | c.242N>T | p.Ala81Val | p.A81V | Q9H0Q0 | protein_coding | tolerated(0.15) | benign(0.409) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FAM49A | SNV | Missense_Mutation | c.824C>T | p.Thr275Ile | p.T275I | Q9H0Q0 | protein_coding | tolerated(0.06) | benign(0.278) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
FAM49A | SNV | Missense_Mutation | c.955N>G | p.Arg319Gly | p.R319G | Q9H0Q0 | protein_coding | deleterious(0) | possibly_damaging(0.647) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FAM49A | SNV | Missense_Mutation | novel | c.491N>A | p.Arg164His | p.R164H | Q9H0Q0 | protein_coding | deleterious(0.03) | possibly_damaging(0.841) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
FAM49A | SNV | Missense_Mutation | novel | c.637N>C | p.Thr213Pro | p.T213P | Q9H0Q0 | protein_coding | tolerated(0.22) | benign(0.251) | TCGA-AA-3867-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |